A Characterization of the Nonclinical Pharmacology and Toxicology of Aficamten, a Reversible Allosteric Inhibitor of Cardiac Myosin
International Journal of Toxicology · 2025
DOI: 10.1177/10915818251326466 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Toxicology, 2025. Verfasst von Michael K Pugsley und 6 weiteren Autor:innen. Beteiligte Einrichtung: Research & Nonclinical Development, Cytokinetics, Inc., South San Francisco, CA, USA. Hauptthemen laut MEDLINE: Cardiac Myosins, Heart. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Cytokinetics.
Abstract (Originalsprache)
Aficamten (CK-3773274) is a cardiac myosin inhibitor in development for the treatment of hypertrophic cardiomyopathy (HCM), a commonly inherited heart condition often characterized as a disease of the sarcomere. Aficamten reduces pathologic cardiac hypercontractility by selectively binding to an allosteric site on cardiac myosin. To characterize the pharmacology and toxicology of aficamten, a series of nonclinical repeated dose studies were conducted. In a 10-day repeated dose pharmacology study in Sprague Dawley rats, aficamten produced dose-dependent reductions in left ventricular fractional shortening (FS) which were fully reversible within 24 h. Aficamten did not change the ratio of heart weight to tibia length (HW/TL) or left ventricular posterior wall (LVPW) thickness at any dose tested. At a supratherapeutic dose of 6 mg/kg/day, there was a significant increase in interventricular septum (IVS) thickness. Aficamten did not affect mRNA expression of the cardiac injury biomarkers BNP, β-MHC, or ANP. In repeated dose Good Laboratory Practice (GLP) regulatory toxicology studies in Sprague Dawley rats for up to 6 months and beagle dogs for up to 9 months, the primary adverse findings at supratherapeutic doses were consistent across all studies and observed in the heart consisting of atrial/ventricular dilatation that correlated with increased heart weights. These findings were largely reversible and consistent with excessive on-target pharmacology associated with cardiac myosin inhibition. The reversible nature of aficamten-associated adverse effects is supportive of its clinical safety as this property suggests that these findings, should they occur in humans, may also be reversible, limiting long-term human cardiac risk.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research & Nonclinical Development, Cytokinetics, Inc., South San Francisco, CA, USA.
- Research & Development, Cytokinetics, Inc., South San Francisco, CA, USA.
ORCID-Profile: Michael K Pugsley
Förderung
- Cytokinetics
Zitieren
APA
Pugsley, M. K., Hwee, D. T., Winters, B. R., Wang, J., Chin, E. R., Morgan, B. P., & Malik, F. I. (2025). A Characterization of the Nonclinical Pharmacology and Toxicology of Aficamten, a Reversible Allosteric Inhibitor of Cardiac Myosin. International Journal of Toxicology. https://doi.org/10.1177/10915818251326466
Vancouver
Pugsley MK, Hwee DT, Winters BR, Wang J, Chin ER, Morgan BP, et al. A Characterization of the Nonclinical Pharmacology and Toxicology of Aficamten, a Reversible Allosteric Inhibitor of Cardiac Myosin. International Journal of Toxicology. 2025. doi:10.1177/10915818251326466
BibTeX
@article{Pugsley2025,
author = {Pugsley, Michael K and Hwee, Darren T and Winters, Brett R and Wang, Jingying and Chin, Eva R and Morgan, Bradley P and Malik, Fady I},
title = {A Characterization of the Nonclinical Pharmacology and Toxicology of Aficamten, a Reversible Allosteric Inhibitor of Cardiac Myosin},
journal = {International Journal of Toxicology},
year = {2025},
doi = {10.1177/10915818251326466}
}
EUVIMED